AIM
SRNE

Acrospire Investment Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Acrospire Investment Management’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-699
Closed -$5K – 2474
2016
Q3 		$5K Buy
+699
New +$4.71K ﹤0.01% 1834

Other funds holding SRNE

WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $490M AUM 35.11% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acrospire Investment Management's SRNE Position: Q4 2016 in Review

Acrospire Investment Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2016, closing a stake of 699 shares — an estimated $5K sold.

Acrospire Investment Management first reported a position in SRNE in Q3 2016 and held it in 1 quarter. The position peaked at $5K in Q3 2016. 68 funds tracked by Wall St. Rank hold SRNE as of Q4 2016.

  • Acrospire Investment Management reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
  • Acrospire Investment Management sold 699 Sorrento Therapeutics, Inc. shares in Q4 2016, an estimated $5K.
  • Acrospire Investment Management first reported a position in Sorrento Therapeutics, Inc. in Q3 2016 and held it in 1 quarter.
  • Acrospire Investment Management's Sorrento Therapeutics, Inc. position peaked at $5K in Q3 2016.
  • 68 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2016.

Based on Acrospire Investment Management's 13F filing for Q4 2016, filed 14 Feb 2017.